Safety of nonsteroidal antiinflammatory drugs and/or paracetamol in people receiving methotrexate for inflammatory arthritis: A Cochrane systematic review

Journal of Rheumatology

Volumn 39, Issue SUPPL. 90, 2012, Pages 62-73

  Colebatch, Alexandra N ^a,b   Marks, Jonathan L ^a   Van Der Heijde, Désirée M ^c   Edwards, Christopher J ^a,d  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b YEOVIL DISTRICT HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Acetaminophen; Ankylosing spondylitis; Methotrexate; Nonsteroidal antiinflammatory drugs; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; ETODOLAC; ETORICOXIB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PIROXICAM; ANALGESIC AGENT; ANTIRHEUMATIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALGESIA; ARTHRITIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE DURATION; DRUG DOSE INCREASE; DRUG SAFETY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FEMALE; GLOMERULUS FILTRATION; HEMATOLOGIC DISEASE; HUMAN; INFLAMMATORY ARTHRITIS; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY TUBULE FUNCTION; LIVER FUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA CLEARANCE; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG INTERACTION; DRUG MONITORING; EXPERT WITNESS; INTERNATIONAL COOPERATION; METHODOLOGY; PAIN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS; ASPIRIN; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; EXPERT TESTIMONY; HUMANS; INTERNATIONAL COOPERATION; METHOTREXATE; PAIN; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84865850394     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120345     Document Type: Review

References (60)

1. Kremer JM. Rational use of new and existing disease modifying agents in rheumatoid arthritis. Ann Intern Med 2001;138:695-706.
2. Mandel MA. The synergistic effect of salicylates on methotrexate toxicity. Plast Reconstr Surg 1976;57:733-7.
3. Furst DE. Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:20-25.
4. Whittle SL, Colebatch AN, Buchbinder R, Edwards CJ, Adams K, Englbrecht M, et al. Multinational evidence-based recommendations for pain management by pharmacotherapy in inflammatory arthritis: Integrating systematic literature research and expert opinion of a broad panel of rheumatologists in the 3e Initiative. Rheumatology 2012 Mar 24. [Epub ahead of print]
5. Colebatch AN, Marks JL, Edwards CJ. Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011;11:CD008872.
6. Higgins JP, Green S, editors. Cochrane handbook for systematic reviews of interventions, version 5.0.2 (updated September 2009). The Cochrane Collaboration; 2009.
7. Sackett DL, Richardson WS, Rosenberg WM, Haynes RB. Evidence-based medicine: How to practice and teach EBM. London, UK: Churchill Livingstone; 1997.
8. European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. London, October 2005. Doc. Ref. EMEA/358234/2005 [Internet. Accessed April 25, 2012.] Available from: http://www.ema.europa.eu/pdfs/ human/press/pus/35823405en.pdf
9. US Food and Drug Administration. FDA alert. Information for healthcare professionals: valdecoxib. Maryland, April 2005. [Internet. Accessed April 25, 2012]. Available from: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124649.htm
10. Therapeutic Goods Administration. Regulator takes tough action on arthritis drugs (&z.ast;amended). Australian Capital Territory, February 2005. [Internet. Accessed April 25, 2012]. Available from: http://www.tga.gov. au/archive/media-2005-arthritis-050210.htm
11. Health Canada. Health Canada has asked Pfizer to suspend sales of its drug Bextra™ and informs Canadians of new restrictions on the use of Celebrex®. Ontario, April 2005. [Internet. Accessed April 25, 2012]. Available from: http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2005/2005- 17-eng.php
12. Medicines and Healthcare Products Regulatory Agency. Lumiracoxib (Prexige): Suspension of marketing authorisations. London, February 2007. [Internet. Accessed April 25, 2012]. Available from: http://www.mhra.gov.uk/ Safetyinformation/Safetywarningsalertsandrecalls/ Safetywarningsandmessagesformedicines/CON2033073
13. Merck. Merck announces voluntary worldwide withdrawal of VIOXX®. New Jersey, September 2004 [Internet. Accessed April 25, 2012.] Available from: http://www.merck.com/newsroom/vioxx/pdf/vioxx-press-release-final.pdf
14. The Canadian Agency for Drugs and Technology in Health. Grey matters: A practical search tool for evidence-based medicine. Ontario, July 2009 [Internet. Accessed April 25, 2012.] Available from: http://www.cadth.ca/en/resources/ grey-matters
15. Higgins J, Altman D. Assessing risk of bias in included studies. Ch. 8. In: Higgins J, Green S, editors. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration; 2008. Collaboration and John Wiley & Sons Ltd.; 2009:187-241.
16. Cochrane Effective Practice and Organisation of Care Group. EPOC data collection checklist. [Internet. Accessed April 25, 2012.] Available from: http://epoc.cochrane.org/sites/ epoc.cochrane.org/files/uploads/ datacollectionchecklist.pdf
17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Department of Epidemiology and Community Medicine, University of Ottawa, Canada; 2000 [Internet. Accessed April 25, 2012.] Available from: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp
18. Khan KS, ter Riet G, Popay J, Nixon N, Kleijnen J. Study quality assessment. In: Khan KS, ter Riet G, Glanville J, Sowden AJ, Kleijnen J, editors. Undertaking systematic reviews of research on effectiveness. CRD's guidance for those carrying out or commissioning reviews. Report 4. 2nd ed. York: York Publishing Services Ltd.; 2001:2.5.1-2.5.10.
19. Oxford Centre for Evidence-based Medicine - Levels of Evidence. March 2009. Oxford, UK. Centre for Evidence Based Medicine. [Internet. Accessed April 25, 2012.] Available from: http://www.cebm.net/index.aspx?o=1025
20. Fathi NH, Mitros F, Hoffman J, Straniero N, Labreque D, Koehnke R, et al. Longitudinal measurement of methotrexate liver concentrations does not correlate with liver damage, clinical efficacy, or toxicity during a 3.5 year double blind study in rheumatoid arthritis. J Rheumatol 2002;29:2092-8.
21. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999;26:2539-43.
22. Schwartz JI, Agrawal NGB, Wong PH, Miller J, Bachmann K, Marbury T, et al. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol 2009;49:1202-9.
23. Anaya JM, Fabre D, Bressolle F, Bologna C, Alric R, Cocciglio M, et al. Effect of etodolac on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1994;21:203-8.
24. Combe B, Edno L, Lafforgue P, Bologna C, Bernard J-C, Acquaviva P, et al. Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. Br J Rheumatol 1995;34:421-8.
25. Seideman P, Müller-Suur R. Renal effects of aspirin and low dose methotrexate in rheumatoid arthritis. Ann Rheum Dis 1993;52:613-5.
26. Stewart CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Rheum 1991;34:1514-20.
27. Franck H, Rau R, Herborn G. Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate. Clin Rheumatol 1996;15:163-7.
28. Fries JF, Singh G, Lenert L, Furst DE. Aspirin, hydroxychloroquine, and hepatic enzyme abnormalities with methotrexate in rheumatoid arthritis. Arthritis Rheum 1990;33:1611-8.
29. Ideguchi H, Ohno S, Ishigatsubo Y. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis. J Clin Rheumatol 2007;13:73-8.
30. Sánchez G, Castro JS, Al Snih S, Blanco LP, Esteva MH, MacGregor EG. Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. Rheumatol Int 2007;27:531-6.
31. Swierkot J, Szechinski J. Side effects of methotrexate treatment in patients with rheumatoid arthritis. Adv Clin Exp Med 2008;17:387-94.
32. Svendsen KB, Ellingsen T, Bech JN, Pfeiffer-Jensen M, Stengaard-Pedersen K, Pedersen EB. Urinary excretion of α-GST and albumin in rheumatoid arthritis patients treated with methotrexate or other DMARDs alone or in combination with NSAIDs. Scand J Rheumatol 2005;34:34-9.
33. Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Leslie A-L, Cook NJ, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol 1994;21:51-4.
34. McKendry RJR, Cyr M. Toxicity of methotrexate compared with azathioprine in the treatment of rheumatoid arthritis. Arch Intern Med 1989;149:685-9.
35. McKendry RJR, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993;20:1850-6.
36. Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 1987;16:186-95.
37. Furst D, Erikson N, Clute L, Koehnke R, Burmeister LF, Kohler JA. Adverse experience with methotrexate during 176 weeks of a longterm prospective trial in patients with rheumatoid arthritis. J Rheumatol 1990;17:1628-35.
38. Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992;23:1400-3.
39. Pillinger MH, Capodici C, Rosenthal P, Kheterpal N, Hanft S, Philips MR, et al. Modes of action of aspirin-like drugs: Salicylates inhibit ERK activation and integrin-dependent neutrophil adhesion. Proc Natl Acad Sci USA 1998;95:14540-5.
40. Ahern M, Booth J, Loxton A, McCarthy P, Meffin P, Kevat S. Methotrexate kinetics in rheumatoid arthritis: Is there an interaction with nonsteroidal antiinflammatory drugs? J Rheumatol 1988;15:1356-60.
41. Iqbal MP, Baig JA, Ali AA, Niazi SK, Mehboobali N, Azmat Hussain M. The effects of non-steroidal anti-inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis. Biopharm Drug Dispos 1998;19:163-7.
42. Kremer JM, Hamilton RA. The effects of nonsteroidal antiinflammatory drugs on methotrexate (MTX) pharmacokinetics: Impairment of renal clearance of MTX at weekly maintenance doses but not at 7.5 mg. J Rheumatol 1995;22:2072-7.
43. Furst DE, Herman RA, Koehnke R, Erickson N, Hash L, Riggs CE, et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990;79:782-6.
44. Tracy TS, Krohn K, Jones DR, Bradley JD, Hall SD, Brater DC. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharmacol 1992;42:121-5.
45. Gumbhir-Shah K, Cevallos WH, DeCleene SA, Korth-Bradley JM. Lack of interaction between bromfenac and methotrexate in patients with rheumatoid arthritis. J Rheumatol 1996;23:984-9.
46. Hübner G, Sander O, Degner FL, Türck D, Rau R. Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis. J Rheumatol 1997;24:845-51.
47. Skeith KJ, Russell AS, Jamali F, Coates J, Friedman H. Lack of significant interaction between low dose methotrexate and ibuprofen or flurbiprofen in patients with arthritis. J Rheumatol 1990;17:1008-10.
48. Stewart CF, Fleming RA, Arkin CR, Evans WE. Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis. Clin Pharmacol Ther 1990;47:540-6.
49. Tracy TS, Worster T, Bradley JD, Greene PK, Brater DC. Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 1994;37:453-6.
50. Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: A systematic review. J Rheumatol 2010;37:1-6.
51. Goldshield Pharmaceuticals Limited. Methotrexate 2.5 mg tablets - Electronic medicines compendium (eMC). Surrey; April 2010. [Internet. Accessed April 25, 2012.] Available from: http://www.medicines.org.uk/EMC/medicine/22954/ SPC/Methotrexate+2.5mg+Tablets/
52. Hospira UK Limited. Package leaflet: Information for the user methotrexate 2.5 mg tablets. Warwickshire; November 2010. [Internet. Accessed April 25, 2012.] Available from: http://www.medicines. org.uk/EMC/medicine/ 15727/PIL/Methotrexate+2.5+mg+Tablets/
53. Société Française de Rhumatologie. Gestes et traitements expliqués. Le methotrexate. Paris; August 2007. [Internet. Accessed April 25, 2012.] Available from: http://www.rhumatologie.asso.fr/data/ fiche/44.pdf
54. Australian Adverse Drug Reactions Bulletin. Core product information for aspirin/codeine combination analgesic. Australia; February 2010. [Internet. Accessed April 25, 2012.] Available from: http://www.tga.gov.au/rtf/forms/otc- template-cmi-codeine-aspirin.rtf
55. Pharmaceutical benefits schedule. Methotrexate tablets. Consumer medicine information. Melbourne; September 2006. [Internet. Accessed April 25, 2012.] Available from: http://www.pbs.gov.au/pbs/pdf-viewer?pdf= %2Fmeds%2Fcmi%2Fhhcmetht20906.pdf
56. Pharmaceutical Management Agency. Methoblastin® tablets. Auckland; March 2010. [Internet. Accessed April 25, 2012.] Available from: http://www.medsafe.govt.nz/Consumers/cmi/m/methoblastin.pdf
57. AETNA clinical policy bulletins. Methotrexate (oral). Hartford; July 2009. [Internet. Accessed April 25, 2012.] Available from: http://aetnahealth. healthline.com/smartsource/healthwisecontent/Multum/d00060a1#d00060a1-drugs
58. Oregon Health Policy and Research. Analgesics/anesthetics, topical. Ohio; April 2010. [Internet. Accessed April 25, 2012.] Available from: http://www.oregon.gov/OHA/pharmacy/therapeutics/docs/ps-2010-04-analgesics- topical.pdf?ga=t
59. Hazardous substances data bank. Naproxen. Bethesda; December 2009. [Internet. Accessed April 25, 2012.] Available from: http://toxnet.nlm.nih.gov/ cgi-bin/sis/search/r?dbs+hsdb:@term+@rn+22204-53-1
60. Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994;37:316.